TMPyP4 tosylate

C[N+]1=CC=C(/C2=C3C=CC(/C(C4=CC=[N+](C)C=C4)=C5C=C/C(N/5)=C(C6=CC=[N+](C)C=C6)/C(C=C/7)=NC7=C(C8=CC=[N+](C)C=C8)/C9=CC=C2N9)=N\3)C=C1.O=S(C%10=CC=C(C)C=C%10)([O-])=O.O=S(C%11=CC=C(C)C=C%11)([O-])=O.O=S(C%12=CC=C(C)C=C%12)([O-])=O.O=S(C%13=CC=C(C)C=C%13)([O-])=O

[1]Chen H, et al. Insuline-like growth factor type I selectively binds to G-quadruplex structures. Biochim Biophys Acta Gen Subj. 2019 Jan;1863 (1) :31-38.|[2]Fujimori J, et al. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. J Orthop Res. 2011 Nov;29 (11) :1707-11.|[3]Fujiwara N, et al. a Stabilizer of Nucleic Acid Secondary Structure, Is a Novel Acetylcholinesterase Inhibitor. PLoS One. 2015 Sep 24;10 (9) :e0139167. |[4]Mikami-Terao Y, et al. Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. Cancer Lett. 2008 Mar 18;261 (2) :226-34. |[5]Grand CL, et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther. 2002 Jun;1 (8) :565-73. Erratum in: Mol Cancer Ther.2003 Feb;2 (2) :208. |[6]Qin G, et al. RNA G-quadruplex formed in SARS-CoV-2 used for COVID-19 treatment in animal models. Cell Discov. 2022 Sep 6;8 (1) :86.